Syros Pharmaceuticals Ownership 2024 | Who Owns Syros Pharmaceuticals Now?
Institutional Ownership
0.00%
Insider Ownership
1.32%
Retail Ownership
98.68%
Institutional Holders
1.00
Syros Pharmaceuticals Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| TEN CAPITAL WEALTH ADVISORS, LLC | - | - | - | -219 | -100.00% | - | Jun 30, 2023 |
Syros Pharmaceuticals's largest institutional shareholder is TEN CAPITAL WEALTH ADVISORS, LLC, holding 0.00% of the company's total share outstanding, currently valued at -. The top 10 institutional shareholders own together 0.00% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| TEN CAPITAL WEALTH ADVISORS, LLC | - | - | - | -219 | -100.00% | - | Jun 30, 2023 |
The largest Syros Pharmaceuticals shareholder by % of total assets is TEN CAPITAL WEALTH ADVISORS, LLC. The company owns 0.00 shares of Syros Pharmaceuticals (SYRS), representing 0.00% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| TEN CAPITAL WEALTH ADVISORS, LLC | - | - | - | -219 | -100.00% | - | Jun 30, 2023 |
As of Jun 30 2023, Syros Pharmaceuticals's largest institutional buyer is TEN CAPITAL WEALTH ADVISORS, LLC. The company purchased -0.22K stocks of SYRS, valued at -.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| TEN CAPITAL WEALTH ADVISORS, LLC | - | - | - | -219 | -100.00% | - | Jun 30, 2023 |
As of Jun 30 2023, Syros Pharmaceuticals's biggest institutional seller is TEN CAPITAL WEALTH ADVISORS, LLC. The company sold -0.22K shares of SYRS, valued at -.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| TEN CAPITAL WEALTH ADVISORS, LLC | - | - | - | -219 | -100.00% | - | Jun 30, 2023 |
Syros Pharmaceuticals's largest sold out institutional shareholder by shares sold is TEN CAPITAL WEALTH ADVISORS, LLC, sold -0.22K shares, valued at -, as of undefined.
Syros Pharmaceuticals Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| Ark ETF Trust | 0.70% | 5,605,575 | - | - | Jan 31, 2024 |
| EntrepreneurShares Series Trust | 0.63% | 168,600 | - | - | Dec 31, 2023 |
| Collaborative Investment Series Trust | 0.15% | 23,261 | - | - | Mar 31, 2024 |
| Federated Hermes MDT Series | 0.09% | 234,008 | - | - | Jan 31, 2024 |
| BRIDGEWAY FUNDS INC | 0.04% | 86,700 | - | - | Mar 28, 2024 |
| ETFis Series Trust I | 0.03% | 36,093 | - | - | Jan 31, 2024 |
| BRIDGEWAY FUNDS INC | 0.02% | 50,670 | 12,000 | 31.03% | Mar 28, 2024 |
| VANGUARD EXPLORER FUND | 0.02% | 236,590 | - | - | Jan 31, 2024 |
| QUANTITATIVE MASTER SERIES LLC | 0.02% | 112,522 | - | - | Mar 31, 2024 |
| FIDELITY SELECT PORTFOLIOS | 0.02% | 1,045,057 | - | - | Feb 29, 2024 |
| DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.01% | 8,330 | - | - | Mar 31, 2024 |
| VANGUARD VALLEY FORGE FUNDS | 0.01% | 5,192 | - | - | Mar 31, 2024 |
| TIAA SEPARATE ACCOUNT VA 1 | 0.01% | 2,140 | - | - | Mar 31, 2024 |
| Federated Hermes MDT Series | 0.01% | 23,401 | - | - | Jan 31, 2024 |
| ALPS ETF Trust | 0.01% | 74,486 | - | - | Feb 29, 2024 |
| VANGUARD INDEX FUNDS | 0.01% | 2,397,164 | - | - | Mar 31, 2024 |
| JPMORGAN INSURANCE TRUST | 0.00% | 63,600 | - | - | Mar 31, 2023 |
| FIDELITY ADVISOR SERIES VII | 0.00% | 32,609 | - | - | Jan 31, 2024 |
| T. Rowe Price Index Trust, Inc. | 0.00% | 78,288 | - | - | Feb 29, 2024 |
| SCHWAB CAPITAL TRUST | 0.00% | 126,988 | - | - | Feb 29, 2024 |
| ETF Managers Trust | 0.00% | 22,267 | - | - | Dec 31, 2023 |
| VANGUARD VARIABLE INSURANCE FUNDS | 0.00% | 149,591 | - | - | Mar 31, 2024 |
| FIDELITY MT VERNON STREET TRUST | 0.00% | 78,738 | - | - | Feb 29, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 453,910 | - | - | Feb 29, 2024 |
| VANGUARD EXPLORER FUND | 0.00% | 23,659 | - | - | Jan 31, 2024 |
| Voya INVESTORS TRUST | 0.00% | 99,300 | - | - | Mar 31, 2024 |
| Calvert Variable Products, Inc. | 0.00% | 3,667 | - | - | Mar 31, 2024 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 38,274 | - | - | Mar 31, 2024 |
| VANGUARD HORIZON FUNDS | 0.00% | 28,048 | - | - | Mar 31, 2024 |
| Voya VARIABLE PORTFOLIOS INC | 0.00% | 22,264 | - | - | Mar 31, 2024 |
| SunAmerica Specialty Series | 0.00% | 342 | - | - | Apr 30, 2021 |
| STATE STREET VARIABLE INSURANCE SERIES FUNDS INC | 0.00% | 2,900 | - | - | Mar 31, 2024 |
| Principal Exchange-Traded Funds | 0.00% | 7,015 | - | - | Mar 31, 2024 |
| GOLDMAN SACHS VARIABLE INSURANCE TRUST | 0.00% | 2,277 | - | - | Mar 31, 2024 |
| TIAA-CREF LIFE FUNDS | 0.00% | 1,268 | - | - | Mar 31, 2024 |
| OHIO NATIONAL FUND INC | 0.00% | 9,014 | - | - | Mar 31, 2024 |
| SCHWAB STRATEGIC TRUST | 0.00% | 251,135 | - | - | Feb 29, 2024 |
| GPS Funds I | 0.00% | 2,005 | - | - | Mar 31, 2024 |
| NEW COVENANT FUNDS | 0.00% | 1,610 | - | - | Dec 31, 2023 |
| Global X Funds | 0.00% | 16,412 | - | - | Jan 31, 2024 |
| RBB FUND, INC. | 0.00% | 31,800 | - | - | Feb 29, 2024 |
| VANGUARD VARIABLE INSURANCE FUNDS | 0.00% | 14,959 | - | - | Mar 31, 2024 |
| OLD WESTBURY FUNDS INC | 0.00% | 29,239 | - | - | Jan 31, 2024 |
| NORTHERN FUNDS | 0.00% | 30,919 | - | - | Mar 28, 2024 |
| Meeder Funds | 0.00% | 916 | - | - | Mar 31, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND II | 0.00% | 2,132 | - | - | Mar 31, 2024 |
| STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 11,100 | - | - | Mar 31, 2024 |
| Direxion Shares ETF Trust | 0.00% | 24,897 | - | - | Jan 31, 2024 |
| RYDEX SERIES FUNDS | 0.00% | 548 | - | - | Dec 31, 2023 |
| Fidelity Rutland Square Trust II | 0.00% | 150,980 | - | - | Feb 29, 2024 |
| FIDELITY SALEM STREET TRUST | 0.00% | 471,385 | - | - | Mar 31, 2024 |
| SCHWAB CAPITAL TRUST | 0.00% | 4,670 | - | - | Jan 31, 2024 |
| ProFunds | 0.00% | 1,232 | - | - | Mar 31, 2024 |
| THRIVENT SERIES FUND INC | 0.00% | 10,701 | - | - | Mar 28, 2024 |
| VANGUARD SCOTTSDALE FUNDS | 0.00% | 193,883 | - | - | Feb 29, 2024 |
| AMERICAN CENTURY ETF TRUST | 0.00% | 8,487 | 8,487 | - | Feb 29, 2024 |
| RYDEX DYNAMIC FUNDS | 0.00% | 304 | - | - | Dec 31, 2023 |
| VALIC Co I | 0.00% | 21,338 | - | - | Feb 29, 2024 |
| NATIONWIDE VARIABLE INSURANCE TRUST | 0.00% | 7,679 | - | - | Mar 31, 2024 |
| Guggenheim Active Allocation Fund | 0.00% | 343 | - | - | Feb 29, 2024 |
| Dimensional ETF Trust | 0.00% | 24,354 | - | - | Jan 31, 2024 |
| THRIVENT MUTUAL FUNDS | 0.00% | 4,833 | - | - | Mar 28, 2024 |
| AMERICAN BEACON FUNDS | 0.00% | 186,593 | - | - | Feb 29, 2024 |
| NATIONWIDE MUTUAL FUNDS | 0.00% | 6,380 | - | - | Jan 31, 2024 |
| PENN SERIES FUNDS INC | 0.00% | 1,400 | - | - | Mar 28, 2024 |
| RYDEX VARIABLE TRUST | 0.00% | 55 | - | - | Dec 31, 2023 |
| COLLEGE RETIREMENT EQUITIES FUND | 0.00% | 47,231 | - | - | Mar 31, 2024 |
| TIAA-CREF FUNDS | 0.00% | 132,614 | - | - | Mar 31, 2024 |
| iSHARES TRUST | 0.00% | 584,396 | - | - | Mar 31, 2024 |
| PACE SELECT ADVISORS TRUST | 0.00% | 11,400 | - | - | Jan 31, 2024 |
| Pacer Funds Trust | 0.00% | 1,619 | - | - | Jan 31, 2024 |
| ALLSPRING MASTER TRUST | 0.00% | 2,163 | - | - | Feb 29, 2024 |
| HC CAPITAL TRUST | 0.00% | 1,063 | - | - | Mar 31, 2024 |
| WILSHIRE MUTUAL FUNDS INC | 0.00% | 9,942 | - | - | Dec 31, 2023 |
| Advisors' Inner Circle Fund II | 0.00% | 24,406 | - | - | Jan 31, 2024 |
| SEI INSTITUTIONAL MANAGED TRUST | 0.00% | 82,109 | - | - | Dec 31, 2023 |
| USAA MUTUAL FUNDS TRUST | 0.00% | 6,089 | - | - | Jan 31, 2024 |
| SPDR SERIES TRUST | 0.00% | 988,068 | - | - | Mar 31, 2024 |
| FLEXSHARES TRUST | 0.00% | 1,936 | - | - | Jan 31, 2024 |
| MASTER INVESTMENT PORTFOLIO | 0.00% | 2,191 | - | - | Mar 31, 2024 |
| Brighthouse Funds Trust II | 0.00% | 21,697 | - | - | Mar 31, 2024 |
| RUSSELL INVESTMENT FUNDS | 0.00% | 2,700 | - | - | Mar 31, 2024 |
| MORGAN STANLEY PATHWAY FUNDS | 0.00% | 2,249 | - | - | Feb 29, 2024 |
| PROSHARES TRUST | 0.00% | 5,503 | - | - | Feb 29, 2024 |
| VANGUARD QUANTITATIVE FUNDS | 0.00% | 100 | - | - | Mar 31, 2024 |
| LINCOLN VARIABLE INSURANCE PRODUCTS TRUST | 0.00% | 51,300 | - | - | Mar 31, 2024 |
| ETF Series Solutions | 0.00% | 384 | - | - | Jan 31, 2024 |
| ALLIANZ VARIABLE INSURANCE PRODUCTS TRUST | 0.00% | 905 | - | - | Dec 31, 2023 |
| NATIONWIDE MUTUAL FUNDS | 0.00% | 2,142 | 2,142 | - | Jan 31, 2024 |
| VANGUARD WELLINGTON FUND | 0.00% | 5,945 | - | - | Feb 29, 2024 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 0.00% | 12,242 | - | - | Jan 31, 2024 |
| iShares U.S. ETF Trust | 0.00% | 1,273 | - | - | Jan 31, 2024 |
| EQ ADVISORS TRUST | 0.00% | 11,235 | - | - | Mar 31, 2024 |
| USAA MUTUAL FUNDS TRUST | 0.00% | 1,798 | - | - | Jan 31, 2024 |
| PACIFIC SELECT FUND | 0.00% | 26,659 | - | - | Mar 31, 2024 |
| Goldman Sachs ETF Trust | 0.00% | 700 | - | - | Feb 29, 2024 |
| PROSHARES TRUST | 0.00% | 1,699 | - | - | Feb 29, 2024 |
| GMO TRUST | 0.00% | 8,300 | - | - | Feb 29, 2024 |
| Legg Mason Global Asset Management Trust | 0.00% | 42,090 | - | - | Jan 31, 2024 |
| MASSMUTUAL SELECT FUNDS | 0.00% | 4,966 | - | - | Dec 31, 2023 |
Syros Pharmaceuticals's largest mutual fund holder by % of total assets is "Ark ETF Trust", owning 5.61M shares, compromising 0.70% of its total assets.
Syros Pharmaceuticals Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 31 Mar, 23 | 1 | - |
| 31 Dec, 22 | 1 | -66.67% |
| 30 Sep, 22 | 3 | -95.16% |
| 30 Jun, 22 | 62 | -31.87% |
| 31 Mar, 22 | 91 | 1.11% |
| 31 Dec, 21 | 90 | -10.89% |
| 30 Sep, 21 | 101 | -4.72% |
| 30 Jun, 21 | 106 | -2.75% |
| 31 Mar, 21 | 109 | 4.81% |
| 31 Dec, 20 | 104 | 13.04% |
| 30 Sep, 20 | 92 | 15.00% |
| 30 Jun, 20 | 80 | 23.08% |
| 31 Mar, 20 | 65 | -12.16% |
| 31 Dec, 19 | 74 | 17.46% |
| 30 Sep, 19 | 63 | -7.35% |
| 30 Jun, 19 | 68 | 6.25% |
| 31 Mar, 19 | 64 | -5.88% |
| 31 Dec, 18 | 68 | -12.82% |
| 30 Sep, 18 | 78 | -1.27% |
| 30 Jun, 18 | 79 | 31.67% |
| 31 Mar, 18 | 60 | -16.67% |
| 31 Dec, 17 | 72 | 5.88% |
| 30 Sep, 17 | 68 | 44.68% |
| 30 Jun, 17 | 47 | 6.82% |
| 31 Mar, 17 | 44 | 10.00% |
| 31 Dec, 16 | 40 | 14.29% |
| 30 Sep, 16 | 35 | 191.67% |
| 30 Jun, 16 | 12 | - |
As of 31 Mar 23, 1 institutions are holding Syros Pharmaceuticals's shares, representing an increase of 0.00% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 31 Mar, 23 | 219 | - |
| 31 Dec, 22 | 219 | -99.98% |
| 30 Sep, 22 | 881,719 | -97.52% |
| 30 Jun, 22 | 35,569,373 | -20.26% |
| 31 Mar, 22 | 44,604,457 | -12.84% |
| 31 Dec, 21 | 51,176,664 | 2.10% |
| 30 Sep, 21 | 50,124,752 | -1.48% |
| 30 Jun, 21 | 50,879,544 | -20.28% |
| 31 Mar, 21 | 63,819,043 | 12.79% |
| 31 Dec, 20 | 56,584,134 | 22.93% |
| 30 Sep, 20 | 46,027,873 | 2.99% |
| 30 Jun, 20 | 44,689,432 | -0.42% |
| 31 Mar, 20 | 44,878,646 | 6.40% |
| 31 Dec, 19 | 42,178,664 | -2.08% |
| 30 Sep, 19 | 43,076,627 | 23.61% |
| 30 Jun, 19 | 34,849,686 | 46.26% |
| 31 Mar, 19 | 23,827,870 | 7.16% |
| 31 Dec, 18 | 22,234,906 | 7.82% |
| 30 Sep, 18 | 20,621,444 | 0.93% |
| 30 Jun, 18 | 20,432,229 | 10.40% |
| 31 Mar, 18 | 18,506,778 | 16.56% |
| 31 Dec, 17 | 15,877,964 | 4.21% |
| 30 Sep, 17 | 15,236,873 | -2.37% |
| 30 Jun, 17 | 15,606,516 | 21.10% |
| 31 Mar, 17 | 12,887,377 | -0.27% |
| 31 Dec, 16 | 12,922,316 | 1.29% |
| 30 Sep, 16 | 12,757,194 | 2.27% |
| 30 Jun, 16 | 12,474,230 | - |
Syros Pharmaceuticals (SYRS) has 219.00 shares outstanding as of 31 Mar 23, up 0.00% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 31 Mar, 23 | 0.00% | 125000.00% |
| 31 Dec, 22 | 0.00% | 0.01% |
| 30 Sep, 22 | 3.17% | 1.94% |
| 30 Jun, 22 | 12.78% | 4.98% |
| 31 Mar, 22 | 16.02% | 4.74% |
| 31 Dec, 21 | 18.38% | 5.67% |
| 30 Sep, 21 | 18.00% | 5.39% |
| 30 Jun, 21 | 18.27% | 3.48% |
| 31 Mar, 21 | 22.92% | 5.55% |
| 31 Dec, 20 | 20.32% | 7.44% |
| 30 Sep, 20 | 16.53% | 6.42% |
| 30 Jun, 20 | 16.05% | 6.18% |
| 31 Mar, 20 | 16.12% | 7.02% |
| 31 Dec, 19 | 15.15% | 6.33% |
| 30 Sep, 19 | 15.47% | 9.88% |
| 30 Jun, 19 | 12.52% | 17.09% |
| 31 Mar, 19 | 8.56% | 13.42% |
| 31 Dec, 18 | 7.99% | 14.56% |
| 30 Sep, 18 | 7.41% | 13.75% |
| 30 Jun, 18 | 7.34% | 16.61% |
| 31 Mar, 18 | 6.65% | 20.44% |
| 31 Dec, 17 | 5.70% | 19.04% |
| 30 Sep, 17 | 5.47% | 17.42% |
| 30 Jun, 17 | 5.61% | 26.16% |
| 31 Mar, 17 | 4.63% | 21.49% |
| 31 Dec, 16 | 4.64% | 22.11% |
| 30 Sep, 16 | 4.58% | 22.83% |
| 30 Jun, 16 | 4.48% | - |
As of 31 Mar 23, Syros Pharmaceuticals is held by 0.00% institutional shareholders, representing a 125000.00% growth compared to 31 Dec 22.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 31 Mar, 23 | - | - |
| 31 Dec, 22 | - | -100.00% |
| 30 Sep, 22 | 1 | -96.30% |
| 30 Jun, 22 | 27 | -32.50% |
| 31 Mar, 22 | 40 | -4.76% |
| 31 Dec, 21 | 42 | -2.33% |
| 30 Sep, 21 | 43 | -34.85% |
| 30 Jun, 21 | 66 | 10.00% |
| 31 Mar, 21 | 60 | - |
| 31 Dec, 20 | 60 | 42.86% |
| 30 Sep, 20 | 42 | -25.00% |
| 30 Jun, 20 | 56 | 75.00% |
| 31 Mar, 20 | 32 | -33.33% |
| 31 Dec, 19 | 48 | 60.00% |
| 30 Sep, 19 | 30 | -38.78% |
| 30 Jun, 19 | 49 | 58.06% |
| 31 Mar, 19 | 31 | -6.06% |
| 31 Dec, 18 | 33 | -2.94% |
| 30 Sep, 18 | 34 | -39.29% |
| 30 Jun, 18 | 56 | 60.00% |
| 31 Mar, 18 | 35 | -20.45% |
| 31 Dec, 17 | 44 | -10.20% |
| 30 Sep, 17 | 49 | 44.12% |
| 30 Jun, 17 | 34 | 47.83% |
| 31 Mar, 17 | 23 | -4.17% |
| 31 Dec, 16 | 24 | -14.29% |
| 30 Sep, 16 | 28 | 133.33% |
| 30 Jun, 16 | 12 | - |
- institutional shareholders have increased their position in SYRS stock as of 31 Mar 23 compared to - in the previous quarter (a 0.00% increase).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 31 Mar, 23 | - | - |
| 31 Dec, 22 | - | -100.00% |
| 30 Sep, 22 | 1 | -95.65% |
| 30 Jun, 22 | 23 | -25.81% |
| 31 Mar, 22 | 31 | -3.13% |
| 31 Dec, 21 | 32 | -8.57% |
| 30 Sep, 21 | 35 | 66.67% |
| 30 Jun, 21 | 21 | -25.00% |
| 31 Mar, 21 | 28 | -3.45% |
| 31 Dec, 20 | 29 | -21.62% |
| 30 Sep, 20 | 37 | 117.65% |
| 30 Jun, 20 | 17 | -29.17% |
| 31 Mar, 20 | 24 | 50.00% |
| 31 Dec, 19 | 16 | -5.88% |
| 30 Sep, 19 | 17 | 21.43% |
| 30 Jun, 19 | 14 | -36.36% |
| 31 Mar, 19 | 22 | 4.76% |
| 31 Dec, 18 | 21 | -16.00% |
| 30 Sep, 18 | 25 | 108.33% |
| 30 Jun, 18 | 12 | 33.33% |
| 31 Mar, 18 | 9 | -30.77% |
| 31 Dec, 17 | 13 | 44.44% |
| 30 Sep, 17 | 9 | 80.00% |
| 30 Jun, 17 | 5 | -28.57% |
| 31 Mar, 17 | 7 | 40.00% |
| 31 Dec, 16 | 5 | 25.00% |
| 30 Sep, 16 | 4 | - |
| 30 Jun, 16 | - | - |
- institutional shareholders have reduced their position in SYRS stock as of 31 Mar 23 compared to - in the previous quarter (a 0.00% increase).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 31 Mar, 23 | 1 | - | 219 | - | 0.00% | 125000.00% | - | - | - | - |
| 31 Dec, 22 | 1 | -66.67% | 219 | -99.98% | 0.00% | 0.01% | - | -100.00% | - | -100.00% |
| 30 Sep, 22 | 3 | -95.16% | 881,719 | -97.52% | 3.17% | 1.94% | 1 | -96.30% | 1 | -95.65% |
| 30 Jun, 22 | 62 | -31.87% | 35,569,373 | -20.26% | 12.78% | 4.98% | 27 | -32.50% | 23 | -25.81% |
| 31 Mar, 22 | 91 | 1.11% | 44,604,457 | -12.84% | 16.02% | 4.74% | 40 | -4.76% | 31 | -3.13% |
| 31 Dec, 21 | 90 | -10.89% | 51,176,664 | 2.10% | 18.38% | 5.67% | 42 | -2.33% | 32 | -8.57% |
| 30 Sep, 21 | 101 | -4.72% | 50,124,752 | -1.48% | 18.00% | 5.39% | 43 | -34.85% | 35 | 66.67% |
| 30 Jun, 21 | 106 | -2.75% | 50,879,544 | -20.28% | 18.27% | 3.48% | 66 | 10.00% | 21 | -25.00% |
| 31 Mar, 21 | 109 | 4.81% | 63,819,043 | 12.79% | 22.92% | 5.55% | 60 | - | 28 | -3.45% |
| 31 Dec, 20 | 104 | 13.04% | 56,584,134 | 22.93% | 20.32% | 7.44% | 60 | 42.86% | 29 | -21.62% |
| 30 Sep, 20 | 92 | 15.00% | 46,027,873 | 2.99% | 16.53% | 6.42% | 42 | -25.00% | 37 | 117.65% |
| 30 Jun, 20 | 80 | 23.08% | 44,689,432 | -0.42% | 16.05% | 6.18% | 56 | 75.00% | 17 | -29.17% |
| 31 Mar, 20 | 65 | -12.16% | 44,878,646 | 6.40% | 16.12% | 7.02% | 32 | -33.33% | 24 | 50.00% |
| 31 Dec, 19 | 74 | 17.46% | 42,178,664 | -2.08% | 15.15% | 6.33% | 48 | 60.00% | 16 | -5.88% |
| 30 Sep, 19 | 63 | -7.35% | 43,076,627 | 23.61% | 15.47% | 9.88% | 30 | -38.78% | 17 | 21.43% |
| 30 Jun, 19 | 68 | 6.25% | 34,849,686 | 46.26% | 12.52% | 17.09% | 49 | 58.06% | 14 | -36.36% |
| 31 Mar, 19 | 64 | -5.88% | 23,827,870 | 7.16% | 8.56% | 13.42% | 31 | -6.06% | 22 | 4.76% |
| 31 Dec, 18 | 68 | -12.82% | 22,234,906 | 7.82% | 7.99% | 14.56% | 33 | -2.94% | 21 | -16.00% |
| 30 Sep, 18 | 78 | -1.27% | 20,621,444 | 0.93% | 7.41% | 13.75% | 34 | -39.29% | 25 | 108.33% |
| 30 Jun, 18 | 79 | 31.67% | 20,432,229 | 10.40% | 7.34% | 16.61% | 56 | 60.00% | 12 | 33.33% |
| 31 Mar, 18 | 60 | -16.67% | 18,506,778 | 16.56% | 6.65% | 20.44% | 35 | -20.45% | 9 | -30.77% |
| 31 Dec, 17 | 72 | 5.88% | 15,877,964 | 4.21% | 5.70% | 19.04% | 44 | -10.20% | 13 | 44.44% |
| 30 Sep, 17 | 68 | 44.68% | 15,236,873 | -2.37% | 5.47% | 17.42% | 49 | 44.12% | 9 | 80.00% |
| 30 Jun, 17 | 47 | 6.82% | 15,606,516 | 21.10% | 5.61% | 26.16% | 34 | 47.83% | 5 | -28.57% |
| 31 Mar, 17 | 44 | 10.00% | 12,887,377 | -0.27% | 4.63% | 21.49% | 23 | -4.17% | 7 | 40.00% |
| 31 Dec, 16 | 40 | 14.29% | 12,922,316 | 1.29% | 4.64% | 22.11% | 24 | -14.29% | 5 | 25.00% |
| 30 Sep, 16 | 35 | 191.67% | 12,757,194 | 2.27% | 4.58% | 22.83% | 28 | 133.33% | 4 | - |
| 30 Jun, 16 | 12 | - | 12,474,230 | - | 4.48% | - | 12 | - | - | - |
Syros Pharmaceuticals Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Insider Sells
All Insider Owners Trades
The last insider sell of Syros Pharmaceuticals's stock was made by Young Richard A on Jul 02 2024, selling 34,837 shares at $5.12 per share (valued at $178.37K).
Syros Pharmaceuticals Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q2 2024 | 20 | 9 | 222.22% |
| Q1 2024 | 11 | 12 | 91.67% |
| Q4 2023 | 8 | 19 | 42.11% |
| Q3 2023 | 4 | 5 | 80.00% |
| Q2 2023 | 18 | 6 | 300.00% |
| Q1 2023 | 12 | 6 | 200.00% |
| Q4 2022 | 15 | 2 | 750.00% |
| Q3 2022 | 35 | - | - |
| Q2 2022 | 13 | 4 | 325.00% |
| Q1 2022 | 16 | 1 | 1600.00% |
| Q4 2021 | 1 | - | - |
| Q3 2021 | 2 | 1 | 200.00% |
| Q2 2021 | 8 | 2 | 400.00% |
| Q1 2021 | 7 | 4 | 175.00% |
| Q4 2020 | 5 | 9 | 55.56% |
| Q3 2020 | 3 | 10 | 30.00% |
| Q2 2020 | 8 | 6 | 133.33% |
| Q1 2020 | 6 | 1 | 600.00% |
| Q4 2019 | 4 | 3 | 133.33% |
| Q3 2019 | - | 5 | - |
20 total buy trades, and 9 total sell trades (buy/sell ratio of 2.22%) were made by Syros Pharmaceuticals's insiders, as of Q2 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q2 2024 | - | 2 | - |
| Q1 2024 | - | - | - |
| Q4 2023 | 1 | 2 | 50.00% |
| Q3 2023 | - | 2 | - |
| Q2 2023 | - | - | - |
| Q1 2023 | - | - | - |
| Q4 2022 | - | - | - |
| Q3 2022 | 2 | - | - |
| Q2 2022 | - | - | - |
| Q1 2022 | - | 1 | - |
| Q4 2021 | - | - | - |
| Q3 2021 | - | 1 | - |
| Q2 2021 | - | - | - |
| Q1 2021 | - | 3 | - |
| Q4 2020 | - | 6 | - |
| Q3 2020 | - | 8 | - |
| Q2 2020 | 1 | 6 | 16.67% |
| Q1 2020 | - | 1 | - |
| Q4 2019 | 2 | - | - |
| Q3 2019 | - | 5 | - |
As of Q2 2024, Insider owners conducted 0 open market buy trades and 2 open market sell trades of Syros Pharmaceuticals's stocks.
Syros Pharmaceuticals Peer Ownership
| Ticker | Company |
|---|---|
| GRCL | Gracell Biotechnologies Inc. |
| IDYA | IDEAYA Biosciences, Inc. |
| LRMR | Larimar Therapeutics, Inc. |
| XNCR | Xencor, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| KTTA | Pasithea Therapeutics Corp. |
| RGNX | REGENXBIO Inc. |
| BDTX | Black Diamond Therapeutics, Inc. |
| SPRO | Spero Therapeutics, Inc. |
| QNRX | Quoin Pharmaceuticals, Ltd. |
| SRZN | Surrozen, Inc. |
| SNDX | Syndax Pharmaceuticals, Inc. |
| KRON | Kronos Bio, Inc. |
| PASG | Passage Bio, Inc. |
| BOLT | Bolt Biotherapeutics, Inc. |
| KROS | Keros Therapeutics, Inc. |
| CRNX | Crinetics Pharmaceuticals, Inc. |
| RNXT | RenovoRx, Inc. |
| NLTX | Neurogene Inc. |
| KZR | Kezar Life Sciences, Inc. |
| CHRS | Coherus BioSciences, Inc. |
| FIXX | Q32 Bio Inc. |
SYRS Ownership FAQ
Who Owns Syros Pharmaceuticals?
Syros Pharmaceuticals is owned by institutional shareholders (0.00%), insiders (1.32%), and public (98.68%). The largest institutional shareholder of Syros Pharmaceuticals is TEN CAPITAL WEALTH ADVISORS, LLC (0% of total shares) and the top mutual fund owner is Ark ETF Trust (0.70% of total shares).
Who are the major institutional shareholders of Syros Pharmaceuticals?
Syros Pharmaceuticals's major institutional shareholders are TEN CAPITAL WEALTH ADVISORS, LLC. The top five shareholders own together 0% of the company's share outstanding.
How many Syros Pharmaceuticals shareholders are there?
As of Mar 2023, there are 1 institutional shareholders of Syros Pharmaceuticals.
What percentage of Syros Pharmaceuticals is owned by TEN CAPITAL WEALTH ADVISORS, LLC?
TEN CAPITAL WEALTH ADVISORS, LLC owns 0 shares of Syros Pharmaceuticals, representing 0% of the company's total shares outstanding, valued at $0 (as of Jun 2023).